title: Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC.
abstract: Tumor recurrence after surgical resection of NSCLC obstructs long-term disease-free survival in approximately 50% of cases. Our data suggest that combining circulating tumor cell enumeration (as single cells or clusters) in tumor-draining pulmonary vein and peripheral blood (assessed by CellSearch) at the time of NSCLC surgery better identifies those patients at higher risk for lung cancer recurrence than does peripheral circulating tumor cell number alone.
authors.affiliation: Manchester Thoracic Oncology Centre, North West Lung Centre, University Hospital of South Manchester, Manchester, United Kingdom; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, United Kingdom. Electronic address: philip.crosbie@manchester.ac.uk.
authors.forename: Phil A J
authors.initials: PA
authors.lastname: Crosbie
authors.affiliation: Manchester Thoracic Oncology Centre, North West Lung Centre, University Hospital of South Manchester, Manchester, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, United Kingdom; Department of Thoracic Surgery, University Hospital of South Manchester, Manchester, United Kingdom.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Shah
authors.affiliation: Manchester Thoracic Oncology Centre, North West Lung Centre, University Hospital of South Manchester, Manchester, United Kingdom; Department of Thoracic Surgery, University Hospital of South Manchester, Manchester, United Kingdom.
authors.forename: Piotr
authors.initials: P
authors.lastname: Krysiak
authors.affiliation: Institute of Cancer Sciences, University of Manchester, United Kingdom.
authors.forename: Cong
authors.initials: C
authors.lastname: Zhou
authors.affiliation: Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, United Kingdom.
authors.forename: Karen
authors.initials: K
authors.lastname: Morris
authors.affiliation: Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, United Kingdom.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Tugwood
authors.affiliation: Manchester Thoracic Oncology Centre, North West Lung Centre, University Hospital of South Manchester, Manchester, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, United Kingdom.
authors.forename: Richard
authors.initials: R
authors.lastname: Booton
authors.affiliation: Cancer Research UK Lung Cancer Centre of Excellence, Manchester, United Kingdom; Institute of Cancer Sciences, University of Manchester, United Kingdom; Department of Medical Oncology, The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
authors.forename: Fiona
authors.initials: F
authors.lastname: Blackhall
authors.affiliation: Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, United Kingdom.
authors.forename: Caroline
authors.initials: C
authors.lastname: Dive
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D009364:Neoplasm Recurrence, Local; D009360:Neoplastic Cells, Circulating / Q000378:metabolism* / Q000473:pathology; D011446:Prospective Studies; D011667:Pulmonary Veins / Q000473:pathology*; D015996:Survival Rate
keywords: Circulating tumor cells; Early stage; NSCLC; Recurrence; Surgery